Genomic Vision is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics
News & Events
Genomic Vision Signs a Strategic Partnership with the Imagine Institute, Europe’s Largest Genetic Research and Care Cluster
> Installation of FiberVision® molecular combing platform at Necker-Enfants malades Hospital
> Development of new genetic tests to enrich Genomic Vision's portfolio in new indications
Bagneux, France (December 3, 2015) – Genomic Vision (GV: EN Paris) a French molecular diagnostics company specializing in the development of diagnostic tests for genetic diseases and cancers based on molecular combing technology, today announces the signing of a strategic partnership with the University-Hospital Institute (IHU) Imagine, the largest European genetic research and care cluster. The FiberVision® molecular combing platform has been installed by the Genomic Vision team at the Institute’s campus of the Necker-Enfants Malades Hospital, which cares for 40,000 patients each year, more than half of which have genetic diseases.
This public-private partnership fits with Genomic Vision's strategy for the university hospital market: to form strategic collaborations with Centers of Excellence in genetic diseases and oncogenetics in order to make its innovative technology widely available in medical and academic settings.
The purpose of this collaboration with the IHU Imagine is to identify pathologies caused by complex structural variations that are difficult to identify with existing methods, thus contributing to the creation of new genetic tests that benefit patients and will enrich the Genomic Vision’s product portfolio
"In order to cure a genetic disease, it is first necessary to identify the genes responsible, characterize their mutations and understand the disruptions they generate. This is particularly difficult in the case of large rearrangements within the genome, which are almost undetectable with conventional technologies. Genomic Vision's molecular combing will considerably reinforce our ability to explore those mutations that give rise to numerous pathologies, in order to treat them better," comments Professor Arnold Munnich, M.D., Founder and Director of the Department of Genetics at Necker-Enfants malades Hospital.
Aaron Bensimon, Ph.D., Co-Founder and Chairman of the Board of Genomic Vision, concludes: "The installation of our FiberVision® molecular combing platform in the heart of the largest European genetic research and care cluster is an important advancement for Genomic Vision. This partnership allows us to share our technological know-how in molecular diagnostics with the researchers at the Imagine Institute and create synergies for developing new diagnostic tests that will benefit many patients. The tests arising from this collaboration may create important growth engines for Genomic Vision in new indications with strong potential, while complementing our ongoing developments."
Upcoming financial publication
- Annual Revenue for 2015, Monday, January 18, 2016* (after trading)
* indicative date, which may be subject to change
ABOUT THE IMAGINE INSTITUTE
The mission of the Imagine Institute, the leading European cluster in genetic disease research, care and teaching, is to understand and cure these diseases. Approved as a University-Hospital Institute in 2011, Imagine was founded by AP-HP, Paris Descartes University, Inserm, the Hospitals of Paris-Hospitals of France Foundation, Paris City Hall and AFM-Telethon.
The Institute gathers 850 of the best doctors, researchers and health care staff in a synergy-creating architecture. It is this unprecedented continuum of expertise, associated with the proximity of patients, that allows Imagine to accelerate discoveries and their applications to benefit patients. www.institutimagine.org
AP-HP is an internationally recognized hospital center of European dimension. Its 39 hospitals receive 7 million patients each year: in consultations, the emergency department, scheduled hospitalizations and home visits.
It ensures a public health service for everyone, 24/7, both as a duty and source of pride. AP-HP is the largest employer of Ile-de-France: 95,000 individuals – doctors, researchers, paramedics, administrative staff and laborers – work there. www.aphp.fr
Created in 1964, the French Institute of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale, Inserm) is a public scientific and technical institution, jointly managed by the French Ministry of Higher Education and Research and the French Ministry of Health. Its researchers are dedicated to the study of all diseases, from the most common to the rarest, through their work in biological, medical and community health research. Inserm celebrated its 50th anniversary in 2014. www.inserm.fr
About the Paris Descartes University:
Paris Descartes University, the university of health and human sciences of Paris. With its nine Training and Research Units (UFR) and its Institute of Technology (IUT), the Paris Descartes University covers the entire range of human and health sciences. Its health cluster, the only university in Ile-de-France that includes medicine, pharmacy, dentistry and midwifery, is internationally recognized for the quality of its training and the excellence of its research.
Genomic Vision signs a strategic partnership with the Imagine Institute, the largest European genetic research and care cluster
Genomic Vision: Aaron Bensimon Co-founder, Chairman & CEO Tel.: +33 1 49 08 07 50 email@example.com
NewCap Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh Tel.: +33 1 44 71 94 92 firstname.lastname@example.org
Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes
This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.